WHO ICTRP trial
A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With…
PER-071-06 · Registro Peruano de Ensayos Clínicos (REPEC) · Not Recruiting
Key facts
| Trial ID | PER-071-06 |
|---|---|
| Public title | A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1) |
| Scientific title | COMPARATIVE, PHASE III, MULTICENTER, RANDOMIZED STUDY WITH A GROUP WITH A PLACEBO TO EVALUATE THE EFFECTIVENESS AND SAFETY OF BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY REGIMES IN PATIENTS WITH BREAST METASTASIC CANCER WITHOUT PREVIOUS TREATMENT |
| Primary sponsor | PRODUCTOS ROCHE Q.F.S.A., |
| Registry | Registro Peruano de Ensayos Clínicos (REPEC) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | III |
| Countries | Korea South;Philippines;Singapore;Taiwan;Spain;France;Greece;Netherlands;Norway;United Kindgdom;Russian Federation;Sweden;Ukraine;Australia;Brazil;Canada;Guatemala;Mexico;Panama;Uruguay;United States |
| Conditions | -C509 Breast, unspecified Breast, unspecified;C509;Breast, unspecified |
| Interventions | Group name:ARM A Type of group;1 N° of participants:700 Intervention(s) description:1) Masking treatment phase: This group will be treated with Bevacizumab at a dose of 15 mg / kg, IV, every 3 weeks, until the progression of the disease… |
| Registration date | Oct 25, 2006 |
| Target size | 5 |
| Secondary IDs | NA;NCT00262067;2006-000378-61 |
| Registry page | ins.gob.pe |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: